Alzheimer’s Advocates Ask US Govt to Approve Aduhelm Medicare Reimbursement

In response to Medicare’s decision to only cover the Alzheimer’s drug Aduhelm in clinical trials, patient advocacy groups have begun an ad campaign to convince voters and, ultimately, government agencies to pay for the drug. The administration’s reticence to reimburse the drug due to its high price and limited efficacy in clinical trials. On the other hand, patient groups say that patients need whatever help they can get with the progressive neurodegenerative condition.

According to Deena Beasley of Reuters, “Thousands of patients and doctors have already pressured the Medicare agency with letters, echoing the companies’ assertions that patients should not be cut off from the new drugs once they have been approved. At the same time, many comments praised Medicare for putting curbs on Aduhelm’s use.”

Click here to learn more.

(Source: Reuters, March 13^th, 2022)